$1.17
-0.03 (-2.50%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RNXT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 2 observational · 1 with posted results
Held by 3 tracked-famous managers (CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 1.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| PumaRx Registry TrialNCT06805461observationalSafety of RenovoCath® as assessed by the number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath. | — | Recruiting | Device: RenovoCath® | Solid Tumors | 1,000 | 2029-09-03 | in 1,111 d | 2026-03-30 |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCNCT03257033Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Gemcitabine, nab-paclitaxel · Device: RenovoCath | Locally Advanced Pancreatic Cancer | 190 | Jun 2026 | — | 2025-11-14 |
| Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 CatheterNCT02591082observationalSurvival | — | Completed | Device: RenovoCath™ R120 Catheter | Pancreatic Neoplasms | 25 | 2021-02-26actual | — | 2021-10-20 |
| A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic CancerNCT02237157results2021-05-07Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the PancreasNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: Gemcitabine, local delivery | Pancreatic Cancer | 20 | Sep 2016actual | — | 2021-05-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19